CDC45 (Cell Division Cycle 45)

Molecular docking identified a high-affinity interaction between sorafenib and KIF20A (binding energy: -6.11 kcal/mol), suggesting direct targeting. The current study unveiled KIF20A as a dual regulator of tumor-intrinsic malignancy and immune evasion, positioning sorafenib as a promising therapeutic agent to disrupt KIF20A-driven pathways in gastric adenocarcinoma.

This study systematically characterized two NPC subtypes with distinct stemness features, clinical outcomes, and TIME features. Novel stemness-related markers will provide valuable targets against metastatic or recurrent NPC.

Cell communication analysis showed enhanced interactions between PTTG1-highly expressed cells and fibroblasts, myeloid cells, and endothelial cells; experimental validation confirmed elevated expression of CDC45 and CENPE in the HCC group in addition to PTTG1. Overall, CDC45 and CENPE, as prognostic genes related to PTTG1, provided new research perspectives and potential therapeutic targets for HCC treatment.

ORC6 represents a highly promising novel target for precision therapy in glioma. Potential approaches to target this pathway include disrupting the ORC6-replication axis using existing drugs (such as palbociclib) or natural products (such as baicalin).

Accordingly, therapies targeting MCM2-7/CMG complexes are expected to act selectively on cells with active replicative helicases, preferentially affecting reactivated CSCs that have re-entered the cell cycle and their proliferating progeny, whereas quiescent G0 CSCs are likely refractory unless combined with strategies that induce controlled cell-cycle re-entry. This review summarizes the roles of MCM proteins in CSC phenotypes and highlights advances in MCM-targeted therapy, with particular focus on structural mechanisms of drug-target interactions to guide development of rational design and clinical translation.

An evaluation of the inhibitory effects of these dimers on the proliferation of three hepatoma cell lines indicated that compound 17 was the most active dimer with IC50 values of 1.5 (HepG2), 1.1 (Huh-7), and 1.1 μM (SK-Hep-1), which were 4.7-, 5.5- and 8.0-fold more active than sorafenib, respectively...In vivo experiments showed that compound 17 at 30 and 60 mg/kg inhibited tumor weight up to 76 % and 84 % without causing toxicity to major organs or impairing liver and kidney function. This study suggested compound 17 as a potential antihepatoma therapeutic agent targeting CDC45.

APOD is a prognostic biomarker for cervical cancer, and the prognostic model constructed by identified cervical cancer-related genes can successfully distinguish the prognosis of patients with cervical cancer.

The study highlights the potential diagnostic and prognostic value of mitochondrial fission-related genes, particularly MTFP2, in prostate cancer and underscores the importance of further investigating these pathways as therapeutic targets.

PTTG1 may play a carcinogenic role by promoting the proliferation of ccRCC cells and inhibiting apoptosis. PTTG1 is expected to become a potential diagnostic and prognostic biomarker as well as an immunotherapy target for ccRCC.

Conversely, our results illuminate the complex consequences of replication stress and reveal what happens to the mitotic apparatus during the prolonged SAC-induced mitotic arrest. Because prolonged mitosis is a common event in human cancers, our results could provide useful information for studies on cancer etiology and therapy.

The most differentially 5mC methylation peak was located on chromosome 19, and its methylation was higher in premature senescence. Gene regulation by m6A in replicative senescence and 5mC in premature senescence was enriched in malignant tumors.